Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04582539 · ClinicalTrials.gov registry record · Phase 1
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04582539 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 22 participants.
The verdict
NCT04582539, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
Interventions
- DRUG INCB000928
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-08-19 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04582539
The ClinicalTrials.gov registry entry for NCT04582539 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB000928 is the first listed.
NCT04582539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04582539 about?
NCT04582539 is a clinical study titled "To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma". This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
What is the current status of trial NCT04582539?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2021-08-19. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT04582539?
The interventions under investigation include: INCB000928 (DRUG).
Who is sponsoring clinical trial NCT04582539?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.